3.64
-0.05(-1.36%)
Currency In USD
| Previous Close | 3.69 |
| Open | 3.69 |
| Day High | 3.73 |
| Day Low | 3.63 |
| 52-Week High | 11.16 |
| 52-Week Low | 2.9 |
| Volume | 1.76M |
| Average Volume | 5.59M |
| Market Cap | 321.26M |
| PE | -3.08 |
| EPS | -1.18 |
| Moving Average 50 Days | 3.85 |
| Moving Average 200 Days | 5.69 |
| Change | -0.05 |
If you invested $1000 in Altimmune, Inc. (ALT) since IPO date, it would be worth $27.33 as of September 13, 2025 at a share price of $3.64. Whereas If you bought $1000 worth of Altimmune, Inc. (ALT) shares 5 years ago, it would be worth $274.92 as of September 13, 2025 at a share price of $3.64.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Altimmune to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 26, 2025 11:30 AM GMT
GAITHERSBURG, Md., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will p
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
GlobeNewswire Inc.
Aug 19, 2025 11:30 AM GMT
Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-
Altimmune Board of Directors Appoints Jerry Durso as Chairman
GlobeNewswire Inc.
Aug 11, 2025 11:30 AM GMT
Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, Md., Aug. 11, 2025 (GLOBE NEW